Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
AMEXFinancialsFinancial - Capital MarketsSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ATCH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
No further dilutive equity sales or large debt increases | A supporting condition in ATLASCLEAR HOLDINGS INC's published investment case. The stated target is No new significant equity or debt issuance beyond current levels. | Under Pressure | Company issues significant new equity or debt beyond current obligations | Unregistered equity sales & new debt obligations reported vs no new issuance target Oct 15 filings report unregistered equity sales and new direct financial obligations, confirming dilutive capital allocation. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ATCH is an early-stage financial-services platform expansion, not yet a proven durable compounder. The thesis is on watch: revenue growth and progress in stock locate are offset by widening operating losses and performance well below its industry cohort.
The valuation evidence points to ATCH being cheap versus peers, but confidence in that comparison is low. The snapshot gives no specific market expectations, so it is unclear how much future growth or improvement in losses is already assumed.
Over the multi-year view, platform revenue has grown, and stock locate revenue has expanded substantially, but new correspondent relationships have not yet contributed meaningful revenue. Operating losses widened year over year, recent performance is weak, and the risk label recently moved to high; a guidance cut on the next call is a near-term risk.
The thesis hinges on whether revenue growth, especially from stock locate and new correspondent relationships, can translate into better operating results. Near term, a guidance cut could weigh on the business outlook, while strength among sector bellwethers could support sector momentum; the effect of changing rates is another swing factor in the evidence.
For the next 1 to 3 years, ATCH remains a high-risk platform-growth story with real revenue progress but no demonstrated improvement in operating losses. The long-term thesis depends on converting expansion into stronger financial performance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS improves toward break-even by mid-2027 | A primary condition in ATLASCLEAR HOLDINGS INC's published investment case. The stated target is EPS >= -$0.01 per share. | Broken | EPS remains below -$0.01 per share by FY27 Q2 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches at least $13.5 million in 2026 | A primary condition in ATLASCLEAR HOLDINGS INC's published investment case. The stated target is >= $13.5 million. | Intact | revenue falls below $13.5 million in FY26 | Revenue: $4.202M FY2026-Q3; GAAP. Published target: >= $13.5 million. Annual target cannot be compared with a quarterly or TTM observation. May 13, 20264,201,852 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.02 → $-0.06 · observed estimates
$0.02B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-25 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-09-26 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-09-27 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-09-28 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-09-29 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-09-30 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-01 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-02 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-03 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-04 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-05 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-06 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-07 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-08 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-09 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-10 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-11 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-12 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-13 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-14 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-15 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-16 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-17 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-18 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-19 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-20 | $0.02 | $20,100,000 | 1 / 1 |
| 2026-10-21 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-22 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-23 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-24 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-25 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-26 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-27 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-28 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-29 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-30 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-10-31 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-11-01 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-11-02 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-11-03 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-11-04 | $-0.06 | $26,510,000 | 1 / 1 |
| 2026-11-05 | $-0.06 | $26,510,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.